Genomic aberrations in lung adenocarcinoma in never smokers

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Job, Bastien ^a   Bernheim, Alain ^b   Beau Faller, Michèle ^c   Camilleri Broët, Sophie ^b,d   Girard, Philippe ^e   Hofman, Paul ^f   Mazières, Julien ^g   Toujani, Saloua ^b   Lacroix, Ludovic ^h   Laffaire, Julien ⁱ   Dessen, Philippe ^b,d   Fouret, Pierre ^b,j  

^a Institut de recherche intégrée en Cancérologie à Villejuif   (France)

^b INSERM   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f PASTEUR HOSPITAL   (France)

^g SERVICE DE PNEUMOLOGIE   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ Ligue Nationale Contre le Cancer   (France)

^j SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; HYPOXIA INDUCIBLE FACTOR 1BETA; MYC PROTEIN; PROTEIN MDM2; PROTEIN MDMX; RAS PROTEIN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR ER81; WERNER SYNDROME PROTEIN; DNA;

ADULT; AGED; AMPLICON; ARTICLE; CHROMOSOME 16P; CHROMOSOME 7P; CHROMOSOME 7Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CLUSTER; GENE DELETION; GENE GAIN; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MISCELLANEOUS NAMED GROUPS; NEVER SMOKER; ONCOGENE; ONCOGENE FUS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TELOMERE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CHROMOSOME ABERRATION; GENETIC PREDISPOSITION; GENETICS; GENOMICS; LUNG TUMOR; MIDDLE AGED; MULTIGENE FAMILY;

ADENOCARCINOMA; AGED; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIGENE FAMILY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 78650092715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015145     Document Type: Article

References (50)

1. Subramanian J, Govindan R (2007) Lung cancer in never smokers: a review. J Clin Oncol 25: 561-570.
2. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers-a different disease. Nat Rev Cancer 7: 778-790.
3. International Agency for Research on Cancer (2007) Water, air, soil and food pollutants. Dans:Attibutable Causes of Cancer in France in the Year 2000. Geneva: WHO Press. pp 97-102.
4. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, et al. (2007) Lung cancer incidence in never smokers. J Clin Oncol 25: 472-478.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
6. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
8. Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
9. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, et al. (2006) Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704.
10. Tam IYS, Chung LP, Suen WS, Wang E, Wong MCM, et al. (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653.
11. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, et al. (2009) Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 15: 5646-5661.
12. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
13. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432.
14. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, et al. (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66: 1371-1375.
15. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, et al. (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734.
16. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069- 1075.
17. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, et al. (2010) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190.
18. Wong MP, Lam WK, Wang E, Chiu SW, Lam CL, et al. (2002) Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 62: 4464-4468.
19. Wong MP, Fung L, Wang E, Chow W, Chiu S, et al. (2003) Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 97: 1263-1270.
20. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, et al. (2001) Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61: 1309-1313.
21. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
22. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232-4235.
23. Balsara BR, Testa JR (2002) Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883.
24. Toh C, Lim W (2007) Lung cancer in never-smokers. J Clin Pathol 60: 337-340.
25. Rudin CM, Avila-Tang E, Samet JM (2009) Lung cancer in never smokers: a call to action. Clin Cancer Res 15: 5622-5625.
26. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, et al. (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118: 1556-1564.
27. Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, et al. (2006) STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 16: 1149-1158.
28. Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22: 1540-1542.
29. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
30. Tonon G, Wong K, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102: 9625-9630.
31. Kim T, Yim S, Lee J, Kwon M, Ryu J, et al. (2005) Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 11: 8235-8242.
32. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.
33. Jandrig B, Seitz S, Hinzmann B, Arnold W, Micheel B, et al. (2004) ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2. Oncogene 23: 9295-9302.
34. Gazdar AF, Thun MJ (2007) Lung cancer, smoke exposure, and sex. J Clin Oncol 25: 469-471.
35. Kanoe H, Nakayama T, Hosaka T, Murakami H, Yamamoto H, et al. (1999) Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation. Oncogene 18: 721-729.
36. Tan AY, Manley JL (2009) The TET family of proteins: functions and roles in disease. J Mol Cell Biol 1: 82-92.
37. Tanaka H, Yao M (2009) Palindromic gene amplification-an evolutionarily conserved role for DNA inverted repeats in the genome. Nat Rev Cancer 9: 216-224.
38. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
39. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2008) Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 182: 1-11.
40. Garnis C, Davies JJ, Buys TPH, Tsao M, MacAulay C, et al. (2005) Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 24: 4806-4812.
41. Scott KL, Kabbarah O, Liang M, Ivanova E, Anagnostou V, et al. (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459: 1085-1090.
42. Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, et al. (2009) Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci USA 106: 5312-5317.
43. Agrelo R, Cheng W, Setien F, Ropero S, Espada J, et al. (2006) Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 103: 8822-8827.
44. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
45. Mok TS, Wu Y, Thongprasert S, Yang C, Chu D, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
46. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
47. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253.
48. LaFramboise T (2009) Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37: 4181-4193.
49. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, et al. (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779-784.
50. Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, et al. (2006) Highresolution genomic profiling of chromosomal aberrations using Infinium wholegenome genotyping. Genome Res 16: 1136-1148.